Funding for this research was provided by:
Janssen Research and Development
Received: 23 September 2020
Accepted: 2 December 2020
First Online: 15 February 2021
Ethics approval and consent to participate
: The study was conducted in accordance with the principles of the Declaration of Helsinki, International Conference on Harmonisation Good Clinical Practice guidelines, and applicable regulatory requirements. Independent ethics committees or institutional review boards of all participating sites approved the study protocol and amendments. All patients provided written informed consent.
: Not applicable
: TMK reports consulting for AstraZeneca, Novartis, Takeda, Sanofi, and Bayer, and research funding from AstraZeneca; DHY reports research funding from Janssen; HK, TZ, GG, and ZD are employees of Janssen; MQing and MQi are employees of Janssen and own equity in Janssen; WSK reports research funding from Roche, Kyowa Kirin, Novartis, Janssen, Mundipharma, Celltrion, and Donga; HH, JZ, MY, S-GC, HSE, STL, S-PY, YSong, YLK, JSK, JJ, and YShi have no conflicts to disclose.